Use of Bempedoic Acid for LDL Cholesterol Lowering and Cardiovascular Risk Reduction: a Consensus Document from the Italian Study Group on Atherosclerosis, Thrombosis and Vascular Biology
Overview
Pharmacology
Authors
Affiliations
The clinical benefit of LDL cholesterol (LDL-C) lowering for cardiovascular disease prevention is well documented. This paper from the Italian Study Group on Atherosclerosis, Thrombosis and Vascular Biology summarizes current recommendations for treatment of hypercholesterolemia, barriers to lipid-lowering therapy implementation and tips to overcome them, as well as available evidence on the efficacy and safety of bempedoic acid. We also report an updated therapeutic algorithm for pharmacological LDL-C lowering in view of the introduction of bempedoic acid in clinical practice.
Zhang D, Gou Z, Qu Y, Su X Front Cell Dev Biol. 2025; 12():1482753.
PMID: 39834386 PMC: 11743479. DOI: 10.3389/fcell.2024.1482753.
Monoclonal Anti-PCSK9 Antibodies: Real-World Data.
Guidotti G, Liberati V, Sorrentino A, Lotti E, Crudele F, Rogolino A J Clin Med. 2024; 13(15).
PMID: 39124810 PMC: 11313337. DOI: 10.3390/jcm13154543.